Why Royal Dutch Shell Plc, AstraZeneca plc and Antofagasta plc Should Lag The FTSE 100 Today

Royal Dutch Shell Plc (LON: RDSB), AstraZeneca plc (LON: AZN) and Antofagasta plc (LON: ANTO) are having a down day.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 (FTSEINDICES: ^FTSE) is retreating a little after five sessions of rises in a row, losing 32 points to 6,746 by noon. Although London’s top index has been buoyed in recent days by positive earnings, disappointing results from some of its star members lie behind today’s reversal.

We take a look at three companies holding the FTSE 100 back today:

Royal Dutch Shell

A disappointing performance miss from Royal Dutch Shell sent its shares down 109p (4.8%) to 2,168p this morning. Third-quarter earnings on a current-cost-of-supplies (CCS) basis crashed 32%, to $4.2bn from $6.2bn a year previously — a fall had been expected, but not one that big.

Also on a CCS basis, earnings per share excluding exceptional items fell 32% from a year ago, to 71 cents per share — but Shell’s quarterly dividend has been raised 5% to 45 cents per share.

Chief executive Peter Voser said “We are facing headwinds from weak industry refining margins, and the security situation in Nigeria, which continue to erode the near term outlook“, but reiterated that Shell is committed to rewarding its shareholders through dividends.

AstraZeneca

A third-quarter update from AstraZeneca also caused disappointment, with loss of exclusivity on several drug brands leading to an expected 4% fall in revenue to $6,250m. But that fall, compounded with increased research investment, led to a 20% fall in pre-tax profit to $1,592m and a 16% drop in earnings per share to 99 cents.

But on the upside, the company told us its late-stage pipeline is continuing to grow, with candidates olaparib, selumetinib and benralizumab all progressing to the Phase III clinical programme stage.

Today’s drop takes AstraZeneca shares to a P/E of 10.6 based on full-year forecasts — with a 5.5% dividend yield predicted, could they be a bargain now?

Antofagasta

Our third FTSE 100 faller today is Antofagasta (LSE: AZN), after investors reacted negatively to the copper miner’s Q3 production report.

Volumes of the brown metal were in line with expectations, with 174,200 tonnes of the stuff produced in the quarter — 3.4% down on the previous quarter, but 4.4% up year-to-date. And though output fell 11.7% on the quarter to 67,700 ounces, year-to-date production rose 8% to 230,600 ounces.

Forecasts for the full year are unchanged, but fears of a surplus of copper over the next few years pushing prices down further is what hit the share price today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares mentioned in this article.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is Avon Protection the best stock to buy in the FTSE All-Share index right now?

Here’s a stock I’m holding for recovery and growth from the FTSE All-Share index. Can it be crowned as the…

Read more »

Investing Articles

Down 8.5% this month, is the Aviva share price too attractive to ignore?

It’s time to look into Aviva and the insurance sector while the share price is pulling back from year-to-date highs.

Read more »

Investing Articles

Here’s where I see Vodafone’s share price ending 2024

Valued at just twice its earnings, is the Vodafone share price a bargain or value trap? Our writer explores where…

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

The Darktrace share price jumped 20% today. Here’s why!

After the Darktrace share price leapt by a fifth in early trading, our writer explains why -- and what it…

Read more »

Dividend Shares

850 shares in this dividend giant could make me £1.1k in passive income

Jon Smith flags up one dividend stock for passive income that has outperformed its sector over the course of the…

Read more »

Investing Articles

Unilever shares are flying! Time to buy at a 21% ‘discount’?

Unilever shares have been racing higher this week after a one-two punch of news from the company. Here’s whether I…

Read more »

artificial intelligence investing algorithms
Market Movers

The Microsoft share price surges after results. Is this the best AI stock to buy?

Jon Smith flags up the jump in the Microsoft share price after the latest results showed strong demand for AI…

Read more »

Google office headquarters
Investing Articles

A dividend announcement sends the Alphabet share price soaring. Here’s what investors need to know

As the Alphabet share price surges on the announcement of a dividend, Stephen Wright outlines what investors should really be…

Read more »